A Test in Focus Archives - Insights

Labile Copper Test Enhances Evaluation for Wilson’s Disease: Joshua Bornhorst, Ph.D.

Barbara J. Toman — Tue, 01 Jul 2025 13:00:00 +0000

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

The post Labile Copper Test Enhances Evaluation for Wilson’s Disease: Joshua Bornhorst, Ph.D. appeared first on Insights.

Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D.

Barbara J. Toman — Tue, 24 Jun 2025 13:00:00 +0000

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.

The post Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D. appeared first on Insights.

Quantitative Adenovirus Assay Better Informs Post-Transplant Care: Joseph Yao, M.D.

Barbara J. Toman — Tue, 17 Jun 2025 13:00:00 +0000

Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in immunocompromised transplant patients, especially children.

The post Quantitative Adenovirus Assay Better Informs Post-Transplant Care: Joseph Yao, M.D. appeared first on Insights.

Reflex Test Guides Precise Care for Arsenic Exposure: Paul Jannetto, Ph.D.

Barbara J. Toman — Tue, 15 Apr 2025 13:00:00 +0000

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

The post Reflex Test Guides Precise Care for Arsenic Exposure: Paul Jannetto, Ph.D. appeared first on Insights.

Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP

Barbara J. Toman — Tue, 08 Apr 2025 13:00:00 +0000

Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in survival of the transplanted organ.

The post Comprehensive Genetic Test Guides Prescribing of a Transplant Anti-Rejection Drug: Jessica Wright, Pharm.D., BCACP appeared first on Insights.

Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D.

Barbara J. Toman — Tue, 21 Jan 2025 14:00:00 +0000

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

The post Assay identifies most known membranous nephropathy antigens: Sanjeev Sethi, M.D., Ph.D. appeared first on Insights.

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

Barbara J. Toman — Tue, 24 Sep 2024 13:00:00 +0000

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

The post Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC appeared first on Insights.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

Barbara J. Toman — Tue, 17 Sep 2024 13:00:00 +0000

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

The post Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S. appeared first on Insights.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Barbara J. Toman — Tue, 10 Sep 2024 13:00:00 +0000

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

The post Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. appeared first on Insights.

Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D.

Barbara J. Toman — Tue, 06 Aug 2024 13:00:00 +0000

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

The post Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. appeared first on Insights.